CAMBRIDGE, UK - Sareum Holdings plc (AIM: SAR), a biotech firm specializing in autoimmune and cancer kinase inhibitors, announced today that all resolutions presented at its Annual General Meeting (AGM) were passed with overwhelming support. The AGM, which took place on Thursday, saw shareholders vote on a series of ordinary and special resolutions concerning company operations and governance.
The voting results indicated strong shareholder backing, with the decision to receive the financial statements for the year receiving 99.38% approval. Similarly, resolutions regarding the re-election of board members Mr. Clive Birch and Dr. Michael Owen were passed with over 92% of the votes in favor.
The company's auditor, Shipleys LLP, will continue its role with 98.70% of the votes supporting its re-appointment. The audit committee has also been authorized to determine the auditor's remuneration, a resolution that garnered 99.29% approval.
Additionally, the directors have been granted authority to allot new shares, which was approved by 96.23% of the votes. A special resolution to disapply pre-emption rights, which allows the directors to issue new shares without offering them to existing shareholders first, also passed with 96.30% approval.
The authority to hold general meetings with a minimum notice was confirmed with 99.29% of the votes in favor. These results reflect a solid consensus among shareholders on the proposed resolutions, with votes against resolutions ranging from a low 0.62% to 7.88%.
The detailed proxy voting results, including the percentage of the Issued Share Capital (ISC) voted and votes withheld, were disclosed, ensuring transparency in the voting process. The full text of each resolution can be found in the Notice of AGM available in the Investors section of Sareum's website.
The information provided here is based on a press release statement issued by Sareum Holdings. This announcement marks a step forward in the company's governance and strategic direction as it continues to develop its therapeutic portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.